Drug Buyers 'Astounded' As Celgene Axes $55M Antitrust Deal
Bristol-Myers Squibb's Celgene unit has dropped out of a $55 million deal that would have ended litigation alleging a sweeping scheme to monopolize the market for two cancer drugs that have...To view the full article, register now.
Already a subscriber? Click here to view full article